Ebastine is a new second generation
histamine H1 receptor antagonist that has shown clinical efficacy in the treatment of seasonal and
perennial allergic rhinitis and
chronic urticaria after once-daily administration. This double-blind multicentre randomised placebo-controlled study has investigated the long term efficacy of
ebastine 10mg once daily in the treatment of
chronic urticaria compared with that of
terfenadine 60mg twice daily. At the end of a 3-month treatment period,
ebastine was significantly superior to placebo in improving symptoms of
chronic urticaria (including severity of
itching, number of wheals per day), and its efficacy was similar to that of
terfenadine. In a global assessment of efficacy, investigators considered
chronic urticaria to have improved in 73% of
ebastine recipients compared with 68% and 52% of patients treated with
terfenadine or placebo, respectively. The patients' assessments of efficacy were similar to those of the investigators.
Ebastine was well tolerated, the incidence and nature of adverse events with this agent being similar to those reported in patients treated with
terfenadine or placebo. The most common adverse events were
headache and dry mouth. Thus, these results, which show
ebastine to be an effective and well tolerated agent, indicated that the
drug should be considered for the first-line
therapy of
chronic urticaria.